Prof. Dr. Klaus Langer

Prof. Dr. Klaus Langer

Institutsdirektor

Apotheker

Institut für Pharmazeutische Technologie und Biopharmazie
Corrensstr. 48
D - 48149 Münster

Raum C.110.159

Tel.: +49 (0)251 - 8339860
Fax: +49 (0)251 - 8339308

E-Mail: k.langer [at] uni-muenster [dot] de

  • Forschungsschwerpunkte

    • Drug Targeting mittels Nanotechnologie
    • Zielspezifische Tumortherapie
    • Formulierung von Arzneistoffen
  • Vita

    Akademische Ausbildung

    Habilitation und Venia legendi im Fach "Pharmazeutische Technologie", Goethe-Universität Frankfurt
    -
    Promotionsarbeit im Fach "Pharmazeutische Technologie", Johann Wolfgang Goethe-Universität Frankfurt

    Beruflicher Werdegang

    seit
    Universitätsprofessor für Pharmazeutische Technologie, WWU Münster
    -
    Wissenschaftlicher Mitarbeiter am Institut für Pharmazeutische Technologie, Goethe-Universität Frankfurt
    Gastprofessur für Pharmazeutische Technologie, Karl-Franzens-Universität Graz
    -
    Pharmazeutisches Praktikum in einer Apotheke und bei der STADA Arzneimittel AG

    Preise

    Lehrpreis der WWU 2015 - Jury für die Vergabe des Lehrpreises der WWU
    Preis des Fachbereichs Biochemie, Chemie und Pharmazie für exzellente Lehre - Goethe-Universität, Frankfurt
    Adolf Messer Stiftungspreis 2003 - Adolf Messer Stiftung
  • Projekte

    Laufend
    • Auftragsanalytik (REM, DSC, ...) für den Bereich der Arzneimittelherstellung ( - )
      Drittmittel: Rottendorf Pharma GmbH
    • Verbundprojekt: Zielgesteuerte BioTransporter oral applizierter Photosensibilisatoren zur photodynamischen Therapie gastrointestinaler Carcinome (GITCare) - Teilvorhaben: Nanostrukturierte Trägersysteme und deren biologische Bewertung ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N13423
    • EXC 1003 B1 - Formation and Properties of Epithelial and Endothelial Barriers ( - )
      Drittmittel: DFG - Exzellenzcluster | Förderkennzeichen: EXC1003/1
    Abgeschlossen
    • BioTraP for CCC - Biokonjugate zur peroralen Anwendung für den Transport von Problemarzneistoffen zur Behandlung des Cholangiozellulären Karzinoms ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N11390
    • NanoGene - Stem cell generation and manipulation by nanoparticle mediated gene transfer for the safe clinical application of gene-modified cells ( - )
      Drittmittel: Bundesministerium für Bildung und Forschung | Förderkennzeichen: 13N1I539
    • NanoBrain - ERA-NET Neuron NanoBrain ( - )
      Drittmittel: Sonstige Mittelgeber
    • Schaltbare Nanopartikel als Wirkstoffträger ( - )
      Eigenmittel
    • NanoCancer - Development of cell type specific drug carrier systems for cancer therapy ( - )
      Eigenmittel
    • NanoDrug - Nanopartikuläre Arzneistoffsysteme für die gezielte Tumortherapie ( - )
      Eigenmittel
  • Publikationen

    Aufsätze (Zeitschriften)

    • Gossmann R., Fahrländer E., Hummel M., Mulac D., Brockmeyer J., Langer K. . ‘Comparative examination of adsorption of serum proteins on HSA- and PLGA-based nanoparticles using SDS-PAGE and LC-MS.’ European Journal of Pharmaceutics and Biopharmaceutics 93, Nr. null: 80-87. doi: 10.1016/j.ejpb.2015.03.021.
    • Borgognoni C., Mormann M., Qu Y., Schäfer M., Langer K., Öztürk C., Wagner S., Chen C., Zhao Y., Fuchs H., Riehemann K. . ‘Reaction of human macrophages on protein corona covered TiO2 nanoparticles.’ Nanomedicine: Nanotechnology, Biology, and Medicine 11, Nr. 2: 275-282. doi: 10.1016/j.nano.2014.10.001.
    • Look J, Wilhelm N, von Briesen H, Noske N, Günther C, Langer K, Gorjup E. . ‘Ligand-modified human serum albumin nanoparticles for targeted gene delivery.Mol. Pharm. 12: 3202-3213.
    • Plöger M., Sendker J., Langer K., Schmidt T.J. . ‘Covalent modification of human serum albumin by the natural sesquiterpene lactone parthenolide.Molecules 20.
    • Langer K. . „2nd Pharm School Symposium: Networked study in Münster.“ Pharmazeutische Zeitung 160, Nr. 6.
    • Michaelis M., Agha B., Rothweiler F., Löschmann N., Voges Y., Mittelbronn M., Starzetz T., Harter P.N., Abhari B.A., Fulda S., Westermann F., Riecken K., Spek S., Langer K., Wiese M., Dirks W.G., Zehner R., Cinatl J., Wass M.N., Cinatl jr. J. . ‘Identification of flubendazole as potential anti-neuroblastoma compound in a large cell line screen.Sci. Rep. 5.
    • Afrimzon E., Zurgil N., Sobolev M., Shafran Y., Langer K., Zlatev I., Wronski R., Windisch M., von Briesen H., Schmidt R., Pietrzik C., Deutsch M. . ‘Detection and analysis of human serum albumin nanoparticles within phagocytic cells at the resolution of individual live cell or single 3D multicellular spheroid.’ Journal of Nanoparticle Research 17, Nr. 12: 1-14. doi: 10.1007/s11051-015-3306-9.
    • Fahrländer E., Schelhaas S., Jacobs A., Langer K. . ‘PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterization and quantification of the PEGylation extent.’ Nanotechnology 26, Nr. 14. doi: 10.1088/0957-4484/26/14/145103.
    • Grünebaum J., Söbbing J., Mulac D., Langer K. . ‘Nanoparticulate carriers for photodynamic therapy of cholangiocarcinoma: In vitro comparison of various polymer-based nanoparticles.’ International Journal of Pharmaceutics 496, Nr. 2: 942-952. doi: 10.1016/j.ijpharm.2015.10.023.
    • Spek S., Häuser M., Schäfer M.M., Langer K. . ‘Characterisation of PEGylated PLGA nanoparticles comparing the nanoparticle bulk to the particle surface using UV/Vis spectroscopy, SEC, 1H-NMR spectroscopy, and X-ray photoelectron spectroscopy.Appl. Surf. Sci. 347.
    • Gossmann R., Langer K., Mulac D. . ‘New perspective in the formulation and characterization of didodecyldimethylammonium bromide (DMAB) stabilized poly(lactic-co-glycolic acid) (PLGA) nanoparticles.’ PLoS ONE 10, Nr. 7. doi: 10.1371/journal.pone.0127532.
    • John C, Herz T, Boos J, Langer K, Hempel G. . ‘A novel asymmetrical flow field-flow fractionation for the analysis of PEG asparaginase.Talanta 146: 335-339.
    • Martínez Vera NP, Schmidt R, Langer K, Zlatev I, Wronski R, Auer E, Havas D, Windisch M, von Briesen H, Wagner S, Stab J, Deutsch M, Pietrzik C, Fazekas F, Ropele S. . ‘Tracking of magnetite labeled nanoparticles in the rat brain using MRI.PloS one 9, Nr. 3: e92068. doi: 10.1371/journal.pone.0092068.
    • John C, Langer K. . ‘Asymmetrical flow field-flow fractionation for human serum albumin based nanoparticle characterisation and a deeper insight into particle formation processes.Journal of chromatography. A 1346: 97-106. doi: 10.1016/j.chroma.2014.04.048.
    • Engel A., Ploger M., Mulac D., Langer K. . ‘Asymmetric flow field-flow fractionation (AF4) for the quantification of nanoparticle release from tablets during dissolution testing.’ International Journal of Pharmaceutics 461, Nr. 1: 137-144. doi: 10.1016/j.ijpharm.2013.11.044.
    • Langer K. . „Medicine-related problems in practice: Tablet splitting - (no) a problem? | Arzneimittelbezogene Probleme in der Praxis: Tablettenteilung - (k)ein Problem?PZ Prisma 21, Nr. 2: 75-81.
    • Niehoff A.-C., Moosmann A., Sobbing J., Wiehe A., Mulac D., Wehe C.A., Reifschneider O., Blaske F., Wagner S., Sperling M., Von Briesen H., Langer K., Karst U. . ‘A palladium label to monitor nanoparticle-assisted drug delivery of a photosensitizer into tumor spheroids by elemental bioimaging.’ Metallomics 6, Nr. 1: 77-81. doi: 10.1039/c3mt00223c.
    • Meister S., Zlatev I., Stab J., Docter D., Baches S., Stauber R.H., Deutsch M., Schmidt R., Ropele S., Windisch M., Langer K., Wagner S., Von Briesen H., Weggen S., Pietrzik C.U. . ‘Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood-brain barrier model.’ Alzheimer's Research and Therapy 5, Nr. 6. doi: 10.1186/alzrt225.
    • Storp B, Engel A, Boeker A, Ploeger M, Langer K. . ‘Albumin nanoparticles with predictable size by desolvation procedure.Journal of microencapsulation 29, Nr. 2: 138-46. doi: 10.3109/02652048.2011.635218.
    • Preuß A, Chen K, Hackbarth S, Wacker M, Langer K, Röder B. . ‘Photosensitizer loaded HSA nanoparticles II: In vitro investigations.’ International Journal of Pharmaceutics 404, Nr. 1-2: 308-316. doi: 10.1016/j.ijpharm.2010.11.023.
    • Löw K, Knobloch T, Wagner S, Wiehe A, Engel A, Langer K, von Briesen H. . ‘Comparison of intracellular accumulation and cytotoxicity of free mTHPC and mTHPC-loaded PLGA nanoparticles in human colon carcinoma cells.Nanotechnology 22, Nr. 24: 245102. doi: 10.1088/0957-4484/22/24/245102.
    • Löw K, Wacker M, Wagner S, Langer K, von Briesen H. . ‘Targeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cells.Nanomedicine : nanotechnology, biology, and medicine . doi: 10.1016/j.nano.2010.12.003.
    • Chen K, Wacker M, Hackbarth S, Ludwig C, Langer K, Röder B. . ‘Photophysical evaluation of mTHPC-loaded HSA nanoparticles as novel PDT delivery systems.Journal of photochemistry and photobiology. B, Biology 101, Nr. 3: 340-7. doi: 10.1016/j.jphotobiol.2010.08.006.
    • Preuß A, Hackbarth S, Wacker M, Knobloch T, Langer K, Röder B. . ‘Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.Journal of controlled release : official journal of the Controlled Release Society 148, Nr. 1: e117-e118. doi: 10.1016/j.jconrel.2010.07.089.
    • Preuß A, Chen K, Hackbarth S, Wacker M, Langer K, Röder B. . ‘Photosensitizer loaded HSA nanoparticles II: In vitro investigations.International journal of pharmaceutics 404: 308-316. doi: 10.1016/j.ijpharm.2010.11.023.
    • Wacker M, Chen K, Preuss A, Possemeyer K, Roeder B, Langer K. . ‘Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.International journal of pharmaceutics 393, Nr. 1-2: 253-62. doi: 10.1016/j.ijpharm.2010.04.022.
    • Wagner S, Rothweiler F, Anhorn MG, Sauer D, Riemann I, Weiss EC, Katsen-Globa A, Michaelis M, Cinatl J, Schwartz D, Kreuter J, von Briesen H, Langer K. . ‘Enhanced drug targeting by attachment of an anti alphav integrin antibody to doxorubicin loaded human serum albumin nanoparticles.Biomaterials 31, Nr. 8: 2388-98. doi: 10.1016/j.biomaterials.2009.11.093.
    • Geiler J, Michaelis M, Naczk P, Leutz A, Langer K, Doerr HW, Cinatl J. . ‘N-acetyl-L-cysteine (NAC) inhibits virus replication and expression of pro-inflammatory molecules in A549 cells infected with highly pathogenic H5N1 influenza A virus.’ BIOCHEMICAL PHARMACOLOGY 79, Nr. 3: 413-420. doi: 10.1016/j.bcp.2009.08.025.
    • Steinhauser I, Langer K, Strebhardt K, Spänkuch B. . ‘Uptake of plasmid-loaded nanoparticles in breast cancer cells and effect on Plk1 expression.Journal of drug targeting 17, Nr. 8: 627-37. doi: 10.1080/10611860903118823.
    • Chen K, Preuss A, Hackbarth S, Wacker M, Langer K, Röder B. . ‘Novel photosensitizer-protein nanoparticles for photodynamic therapy: photophysical characterization and in vitro investigations.Journal of photochemistry and photobiology. B, Biology 96, Nr. 1: 66-74. doi: 10.1016/j.jphotobiol.2009.04.006.
    • Holzer M, Vogel V, Mäntele W, Schwartz D, Haase W, Langer K. . ‘Physico-chemical characterisation of PLGA nanoparticles after freeze-drying and storage.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 72, Nr. 2: 428-37.
    • Müller RS, Langer K. . „Nanotechnologie: Nanopartikel bringen Arzneistoffe sicher ans Ziel.“ Pharmazeutische Zeitung 4.
    • Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. . ‘Specific Targeting of HER2 Overexpressing Breast Cancer Cells with Doxorubicin-Loaded Trastuzumab-Modified Human Serum Albumin Nanoparticles.’ BIOCONJUGATE CHEMISTRY 19, Nr. 12: 2321-2331. doi: 10.1021/bc8002452.
    • Anhorn MG, Mahler HC, Langer K. . ‘Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.International journal of pharmaceutics 363, Nr. 1-2: 162-9. doi: 10.1016/j.ijpharm.2008.07.004.
    • Steinhauser IM, Langer K, Strebhardt KM, Spänkuch B. . ‘Effect of trastuzumab-modified antisense oligonucleotide-loaded human serum albumin nanoparticles prepared by heat denaturation.Biomaterials 29, Nr. 29: 4022-8. doi: 10.1016/j.biomaterials.2008.07.001.
    • Michaelis M, Bliss J, Arnold SC, Hinsch N, Rothweiler F, Deubzer HE, Witt O, Langer K, Doerr HW, Wels WS, Cinatl J. . ‘Cisplatin-Resistant Neuroblastoma Cells Express Enhanced Levels of Epidermal Growth Factor Receptor (EGFR) and Are Sensitive to Treatment with EGFR-Specific Toxins.’ CLINICAL CANCER RESEARCH 14, Nr. 20: 6531-6537. doi: 10.1158/1078-0432.CCR-08-0821.
    • Spänkuch B, Steinhauser I, Wartlick H, Kurunci-Csacsko E, Strebhardt KI, Langer K. . ‘Downregulation of Plk1 expression by receptor-mediated uptake of antisense oligonucleotide-loaded nanoparticles.Neoplasia (New York, N.Y.) 10, Nr. 3: 223-34. doi: 10.1593/neo.07916.
    • Langer K, Anhorn MG, Steinhauser I, Dreis S, Celebi D, Schrickel N, Faust S, Vogel V. . ‘Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.International journal of pharmaceutics 347, Nr. 1-2: 109-17. doi: 10.1016/j.ijpharm.2007.06.028.
    • Dreis S, Rothweiler F, Michaelis M, Cinatl J, Kreuter J, Langer K. . ‘Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.International journal of pharmaceutics 341, Nr. 1-2: 207-14. doi: 10.1016/j.ijpharm.2007.03.036.
    • Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, Asmussen B, Kreuter J, Gelperina S. . ‘Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.International journal of pharmaceutics 337, Nr. 1-2: 346-56. doi: 10.1016/j.ijpharm.2007.01.031.
    • Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. . ‘Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.Journal of controlled release : official journal of the Controlled Release Society 118, Nr. 1: 54-8. doi: 10.1016/j.jconrel.2006.12.012.
    • Steinhauser I, Spänkuch B, Strebhardt K, Langer K. . ‘Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells.Biomaterials 27, Nr. 28: 4975-83. doi: 10.1016/j.biomaterials.2006.05.016.
    • Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. . ‘Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.The Journal of pharmacology and experimental therapeutics 317, Nr. 3: 1246-53. doi: 10.1124/jpet.105.097139.
    • Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. . ‘Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes.Biomaterials 26, Nr. 29: 5898-906. doi: 10.1016/j.biomaterials.2005.02.038.
    • Balthasar S, Michaelis K, Dinauer N, von Briesen H, Kreuter J, Langer K. . ‘Preparation and characterisation of antibody modified gelatin nanoparticles as drug carrier system for uptake in lymphocytes.Biomaterials 26, Nr. 15: 2723-32. doi: 10.1016/j.biomaterials.2004.07.047.
    • Wartlick H, Michaelis K, Balthasar S, Strebhardt K, Kreuter J, Langer K. . ‘Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cells.Journal of drug targeting 12, Nr. 7: 461-71. doi: 10.1080/10611860400010697.
    • Michaelis M, Langer K, Arnold S, Doerr HW, Kreuter J, Cinatl J. . ‘Pharmacological activity of DTPA linked to protein-based drug carrier systems.Biochemical and biophysical research communications 323, Nr. 4: 1236-40. doi: 10.1016/j.bbrc.2004.08.223.
    • Brzoska M, Langer K, Coester C, Loitsch S, Wagner TOF, Mallinckrodt CV. . ‘Incorporation of biodegradable nanoparticles into human airway epithelium cells - in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.’ BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 318, Nr. 2: 562-570. doi: 10.1016/j.bbrc.2004.04.067.
    • Brzoska M, Langer K, Coester C, Loitsch S, Wagner TO, Mallinckrodt C. . ‘Incorporation of biodegradable nanoparticles into human airway epithelium cells-in vitro study of the suitability as a vehicle for drug or gene delivery in pulmonary diseases.Biochemical and biophysical research communications 318, Nr. 2: 562-70. doi: 10.1016/j.bbrc.2004.04.067.
    • Wartlick H, Spankuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. . ‘Tumour cell delivery of antisense oligonucleotides by human serum albumin nanoparticles.’ JOURNAL OF CONTROLLED RELEASE 96, Nr. 3: 483-495. doi: 10.1016/j.jconrel.2004.01.029.
    • Wartlick H, Spänkuch-Schmitt B, Strebhardt K, Kreuter J, Langer K. . ‘Tumour cell delivery of antisense oligonuclceotides by human serum albumin nanoparticles.Journal of controlled release : official journal of the Controlled Release Society 96, Nr. 3: 483-95. doi: 10.1016/j.jconrel.2004.01.029.
    • Rhaese S, von Briesen H, Rübsamen-Waigmann H, Kreuter J, Langer K. . ‘Human serum albumin-polyethylenimine nanoparticles for gene delivery.Journal of controlled release : official journal of the Controlled Release Society 92, Nr. 1-2: 199-208.
    • Langer K, Balthasar S, Vogel V, Dinauer N, von Briesen H, Schubert D. . ‘Optimization of the preparation process for human serum albumin (HSA) nanoparticles.International journal of pharmaceutics 257, Nr. 1-2: 169-80. doi: 10.1016/S0378-5173(03)00134-0.
    • Michaelis M, Langer K, Vogel JU, Kreuter J, Rabenau H, Doerr HW, Cinatl J. . ‘In vitro antiviral activity of aphidicolin and its derivates - Synergistic effects of aphidicolin with other antiviral drugs.’ ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 52, Nr. 5: 393-399.
    • Michaelis M, Cinatl J, Cinatl J, Pouckova P, Langer K, Kreuter J, Matousek J. . ‘Coupling of the antitumoral enzyme bovine seminal ribonuclease to polyethylene glycol chains increases its systemic efficacy in mice.’ ANTI-CANCER DRUGS 13, Nr. 2: 149-154. doi: 10.1097/00001813-200202000-00006.
    • Weber C, Reiss S, Langer K. . ‘Preparation of surface modified protein nanoparticles by introduction of sulfhydryl groups.International journal of pharmaceutics 211, Nr. 1-2: 67-78. doi: 10.1016/S0378-5173(00)00590-1.
    • Michaelis M, Vogel JU, Cinati J, Langer K, Kreuter J, Schwabe D, Driever PH, Cinati J. . ‘Cytotoxicity of aphidicolin and its derivatives against neuroblastoma cells in vitro: synergism with doxorubicin and vincristine.’ ANTI-CANCER DRUGS 11, Nr. 6: 479-485. doi: 10.1097/00001813-200007000-00009.
    • Michaelis M, Matousek J, Vogel JU, Slavik T, Langer K, Cinatl J, Kreuter J, Schwabe D, Cinatl J. . ‘Bovine seminal ribonuclease attached to nanoparticles made of polylactic acid kills leukemia and lymphoma cell lines in vitro.Anti-cancer drugs 11, Nr. 5: 369-76. doi: 10.1097/00001813-200006000-00007.
    • Langer K, Coester C, Weber C, von Briesen H, Kreuter J. . ‘Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 49, Nr. 3: 303-7.
    • Coester CJ, Langer K, van Briesen H, Kreuter J. . ‘Gelatin nanoparticles by two step desolvation--a new preparation method, surface modifications and cell uptake.Journal of microencapsulation 17, Nr. 2: 187-93. doi: 10.1080/026520400288427.
    • Coester CJ, Langer K, Von Briesen H, Kreuter J. . ‘Gelatin nanoparticles by two step desolvation - a new preparation method, surface modifications and cell uptake.’ JOURNAL OF MICROENCAPSULATION 17, Nr. 2: 187-193.
    • Coester C, Kreuter J, von Briesen H, Langer K. . ‘Preparation of avidin-labelled gelatin nanoparticles as carriers for biotinylated peptide nucleic acid (PNA).International journal of pharmaceutics 196, Nr. 2: 147-9. doi: 10.1016/S0378-5173(99)00409-3.
    • Weber C, Kreuter J, Langer K. . ‘Desolvation process and surface characteristics of HSA-nanoparticles.International journal of pharmaceutics 196, Nr. 2: 197-200. doi: 10.1016/S0378-5173(99)00420-2.
    • Weber C, Coester C, Kreuter J, Langer K. . ‘Desolvation process and surface characterisation of protein nanoparticles.’ INTERNATIONAL JOURNAL OF PHARMACEUTICS 194, Nr. 1: 91-102. doi: 10.1016/S0378-5173(99)00370-1.
    • Weber C, Michaelis M, Vogel JU, Cinatl J, Kreuter J, Langer K. . ‘Simple and efficient method for the detection of diethylenetriaminepentaacetic acid.’ JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND L 736, Nr. 1-2: 299-303. doi: 10.1016/S0378-4347(99)00456-9.
    • Aliautdin RN, Petrov VE, Langer K, Berthold A, Kreuter J, Kharkevich DA. . ‘The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles | Dostavka loperamida v mozg s pomoshch'iu polibutiltsianoarilatnykh nanochastits.Eksperimental'naia i klinicheskaia farmakologiia 61, Nr. 1: 17-20.
    • Aliautdin RN, Petrov VE, Langer K, Berthold A, Kreuter J, Kharkevich DA. . ‘[The delivery of loperamide to the brain by using polybutyl cyanoacrylate nanoparticles].’ Eksperimental'naia i klinicheskaia farmakologiia 61, Nr. 1: 17-20.
    • Langer K, Lambrecht G, Moser U, Mutschler E, Kreuter J. . ‘Quantitative colorimetric and gas chromatographic determination of arecaidine propargyl ester.’ Journal of Chromatography B: Biomedical Applications 692, Nr. 2: 345-350. doi: 10.1016/S0378-4347(96)00521-X.
    • Langer K, Zimmer A, Kreuter J. . ‘Acrylic nanoparticles for ocular drug delivery.’ S.T.P. Pharma Sciences 7, Nr. 6: 445-451.
    • Langer K, Mutschler E, Lambrecht G, Mayer D, Troschau G, Stieneker F, Kreuter J. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part III: Evaluation as drug delivery system for ophthalmic applications.’ International Journal of Pharmaceutics 158, Nr. 2: 219-231. doi: 10.1016/S0378-5173(97)00255-X.
    • Langer K, Stieneker F, Lambrecht G, Mutschler E, Kreuter J. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part II: Arecaidine propargyl ester and pilocarpine loading and in vitro release.’ International Journal of Pharmaceutics 158, Nr. 2: 211-217. doi: 10.1016/S0378-5173(97)00256-1.
    • Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. . ‘Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.Pharmaceutical research 14, Nr. 3: 325-8. doi: 10.1023/A:1012098005098.
    • Pirker S, Kruse J, Noe Ch, Langer K, Zimmer A, Kreuter J. . ‘Characterization of polybutyleyanoacrylate nanoparticles. Part II: Determination of polymer content by NMR-analysis.’ International Journal of Pharmaceutics 128, Nr. 1-2: 189-195. doi: 10.1016/0378-5173(95)04305-5.
    • Langer K, Marburger C, Berthold A, Kreuter J, Stieneker F. . ‘Methylmethacrylate sulfopropylmethacrylate copolymer nanoparticles for drug delivery. Part I: Preparation and physicochemical characterization.’ International Journal of Pharmaceutics 137, Nr. 1: 67-74. doi: 10.1016/0378-5173(96)89589-5.
    • Langer K, Seegmuller E, Zimmer A, Kreuter J. . ‘Characterisation of polybutylcyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans.’ International Journal of Pharmaceutics 110, Nr. 1: 21-27. doi: 10.1016/0378-5173(94)90371-9.

    Buchbeiträge (Sammel- Herausgeberbände)

    • Langer, K. . „Überblick über Messmethoden und deren physikalische Hintergründe: Submikron.“ In Partikel in der Pharmaproduktion, herausgegeben von Stieneker, F (Hrsg.): , 67-96.
    • Langer K. . „Peptide nanoparticles.“ In Nanotechnologies for the Life Sciences, Vol. 2: Biological and Pharmaceutical Nanomaterials, herausgegeben von Kumar C (Hrsg.): , 145-184.

    Kurzbeiträge (Poster)

    • Gisbert Fenoy C, Raudszus B, Zlatev I, Nienberg C, Langer K, Jose J.Screening of nanoparticles for drug-delivery across the blood-brain barrier using autodisplayed LRP1 IV-domain on E. coli.Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Elfering S, Langer K, Wünsch B.Development of pH-responsive human serum albumin (HSA) nanoparticles: a possible new tool for cancer therapy.Poster contributed to the 1st Joint European conference on therapeutic targets and medicinal chemistry (TTMC 2015), Münster, Germany, .
    • Gossmann R, Hummel M, Mulac D, Brockmeyer J, Langer K.Cationic nanoparticles. An analytical approach to biological relevance.Poster contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Mesken J, Langer K.Polyarginine modified human serum albumin (HSA) nanoparticles for effective cell transfection.Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Horster L, Bernhardt A, Krenzlin S, Kiehm K, Langer K.Fluid bed granulation for the incorporation of polymeric nanoparticles into lactose granules.Poster contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Lappe S, Langer K.Investigating the influence of glass transition temperature on the release behaviour of flurbiprofen- and mTHPP-loaded poly(D,L-lactic-co-glycolic acid) nanoparticles.Poster contributed to the 1st European Conference on Pharmaceutics – Drug Delivery, Reims, France, .
    • Lappe S, Langer K.The glass transition temperature as an underestimated parameter for drug release properties of polymer based nanoparticles.Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Raudszus B, Langer K.Vinyl sulfone-poly(vinyl alcohol)-stabilized PLA-nanoparticles as reactive particle system for various surface modifications.Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Pieper S, Langer K.Entrapment of doxorubicin in different nanoparticle systems - an overview.“Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Thoma F, Langer K.Lipoproteins as new protein delivery system.Poster contributed to the DPhG Annual Meeting, Düsseldorf, Germany, .
    • Grünebaum, J., Söbbing, J., Mulac, D., Langer, K.Improved photocytotoxicity in cholangiocelullar carcinoma cell lines with mTHPP-loaded PLGA nanoparticles.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Moosmann, A., Klein, J.-C., Kurz, C., Knoll, T., Söbbing, J., Wieland, G., Langer, K., von Briesen, H., Wagner, S.Transport of nanoparticles across the intestinal barrier.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Krenzlin, S., Wieland, G., Langer, K., Wagner, S., Frankenfeld, K., Anczykowski, B., Spallek, M.Innovation in PDT: Oral administration of photosensitizers in treatment of cholangiocellular carcinoma.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Söbbing, J., Grünebaum, J., Mulac, D., Langer, K.Are polymeric nanoparticles able to cross the gastrointestinal barrier?Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Fahrländer, E., Langer, K.PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterisation and quantification of the PEGylation extent.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Mulac, D., Fahrländer, E., Gossmann, R., Langer, K.Comparative examination of adsorption of serum proteins on HSA and PLGA based nanoparticles.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Zlatev, I., Langer, K.Protein modified PLA nanoparticles for active targeting.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Spek, S., Häuser, M., Langer, K.Quantification of residual polyvinyl alcohol and poly (ethylene glycol) in PLGA nanoparticles by SEC, 1H-NMR and UV/VIS spectroscopy.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Look, J., Wilhelm, N., Gorjup, E., von Briesen, H., Noske, N., Rodriguez J.R., Prosper, F., Serra, M., Carrondo, M., Alves, P., Langer, K.Nanoparticles for gene delivery.Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Lappe, S., Langer, K.Glass transition temperature of poly(D,L-lactic-co-glycolic acid) nanoparticles.Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • John, C., Langer, K.Asymmetrical flow field-flow fractionation in combination with inline-coupled dynamic light scattering techniques for analysis of PEGylation of protein nanoparticles.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Gossmann, R., Mulac, D., Hummel, M., Brockmeyer, J., Langer, K.Cationic nanoparticles as a promising drug delivery system? In detail characterization of surface properties.Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Söbbing, J., Mulac, D., Wieland, G., Wiehe, A., Langer, K.Preparation and physico-chemical evaluation of PLGA-nanoparticles for photodynamic tumor therapy.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Wessels, L., Tacke, S., Mulac, D., Langer, K.Nanocapsules - Is the preparation of core-shell structured nanosystems that simple?Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Stab, J., Zlatev, I., Meister, S., Langer, K., Wronski, R., Windisch, M., Ropele, S., Schmidt, R., Deutsch, M., Pietrzik, C., von Briesen, H., Wagner, S.Painkillers for Alzheimer’s disease – A nanoparticle-based approach to transport flurbiprofen to the brain.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Gossmann, R., Mulac, D., Langer, K.New perspective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.“Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lissabon, Portugal, .
    • Herz, T., John, C., Langer, K., Hempel, G.Development and validation of a new analytical method to characterize PEG-asparaginase by flow field-flow fractionation.“Poster contributed to the 35th EORTC-PAMM Winter Meeting, Münster, Germany, .
    • Thoma, F., Langer, K.Strategies to improve colloidal stability of lysozyme-loaded nanoparticles.Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Spek, S., Häuser, M., Schäfer, M., Langer, K.Characterisation of PEGylated nanoparticles comparing the nanoparticle bulk to the particle surface using UV-Vis spectroscopy, SEC, 1H NMR spectroscopy and X-ray photoelectron spectroscopy.Poster contributed to the DPhG Annual Meeting, Frankfurt a.M., Germany, .
    • Fahrländer, E., Langer, K.Characterisation of PEGylated human serum albumin (HSA) as raw material for nanoparticle preparation.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Oppenberg, J., Wilhelm, N., Gorjup, E., von Briesen, H., Noske, N., Huss, R., Rodriguez, J.R., Prosper, F., Serra, M., Carrondo, M., Alves, P., Langer, K.Generation and manipulation of stem cells by a nanoparticle mediated gene delivery system.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Stab, J., Zlatev, I., Meister, S., Langer, K., Wronski, R., Windisch, M., Ropele, S., Schmidt, R., Deutsch, M., Pietrzik, C., von Briesen, H., Wagner, S.Making transport possible: Flurbiprofen-loaded nanoparticles for the treatment of Alzheimer´s disease.“Poster präsentiert auf der 15. Bad Herrenalber Transporter-Tage, Bad Herrenalb, Germany, .
    • Söbbing, J., Grünebaum, J., Mulac, D., Wieland, G., Wiehe, A., Langer, K.Preparation and biological evaluation of mTHPP-loaded PLGA nanoparticles for photodynamic tumor therapy.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Fahrländer, E., Langer, K.PEGylated human serum albumin (HSA) nanoparticles: Preparation, characterisation and quantification of the PEGylation efficiency.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Wessels, L., Hoffmann, M., Weber, F., Düfer, M. Hempel, G., Hensel, A., Jose, J., Langer, K., Lehr, M., Müller, K., Schmidt, T., Wünsch, B.PharMSchool.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • John, C., Langer, K.Asymmetrical flow field-flow fractionation (AF4) with inline-coupled dynamic light-scattering techniques for a deeper insight into nanoparticle formation.Poster contributed to the DPhG Annual Meeting, Freiburg, Germany, .
    • Kohl, Y., Spek, S., Hally, F., Spallek, M.J., Gonnissen, D., Gribbon, P., Wieland, G.D., Wiehe, A., Klein, T., Riehemann, K., von Briesen, H., Langer, K., Wagner, S.Biopolymer nanoparticles for therapeutic applications: Synthesis, characterization and assessment of biocompatibility.Poster contributed to the NanoSafety, Saarbrücken, Germany, .
    • Häuser, M., Langer., K., Schönhoff, M.pH-triggered polyelectrolyte desorption from electrostatically surface modified poly(lactic-co-glycolic acid) nanoparticles.Poster contributed to the 26th Conference of the European Colloid and Interface Society, Malmö, Sweden, .
    • Wilhelm, N., Oppenberg, J., Langer, K., Rodriguez, J.R., Prosper, F., Serra, M., Carrondo, M., Alves, P., Noske, N., Kern, S., Huss, R., Günther, C., von Briesen, H., Gorjup, E.Generation and manipulation of stem cells by a nanoparticle mediated gene delivery system.Poster contributed to the EMBL Conference: Stem cells in cancer and regenerative medicine, Heidelberg, Germany, .
    • Böker, A., Langer, K.Native and reversible protein precipitation for the preparation of nanoparticles.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Istanbul, Turkey, .
    • Häuser, M., Langer., K., Schönhoff, M.pH-triggered polyelectrolyte desorption from electrostatically surface modified poly(lactic-co-glycolic acid) nanoparticles.Poster contributed to the 8. Zsigmondy-Kolloquium der Kolloidgesellschaft, Darmstadt, Germany, .
    • Häuser, M., Langer., K., Schönhoff, M.Investigation of the adsorption of polyarylic acid onto surface modifed poly(lactic-co-glycolic acid) nanoparticles.Poster contributed to the 7. Zsigmondy-Kolloquium der Kolloidgesellschaft, Münster, Germany, .
    • Löw, K., Wacker, M., Wagner, S., Langer, K., von Briesen, H.Accumulation of targeted HSA-nanoparticles in different colon carcinoma cell lines using EGFR-expression.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Preuss, A., Hackbarth, S., Wacker, M., Knobloch, T., Langer, K., Röder, B.Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.Poster contributed to the European Symposium on Controlled Drug Delivery, Egmond aan Zee, Netherlands, .
    • Wacker, M., Preuss, A., Chen, K., Roeder, B., Langer, K.Photosensitizer loaded HSA nanoparticles: Optimization of the preparation process and uptake into Jurkat cells.Poster contributed to the AAPS Annual Meeting and Exposition, New Orleans, USA, .
    • Wacker, M., Preuss, A., Chen, K., Roeder, B., Langer, K.Photosensitizer loaded HSA nanopartcles – Preparation process and cellular uptake.Poster contributed to the GPEN Meeting, Chapel Hill NC, USA, .
    • Preuß, A., Hackbarth, S., Wacker, M., Knobloch, T., Langer, K., Röder, B.Comprehensive in vitro investigations on biodegradable photosensitizer-nanoparticle delivery systems.Poster contributed to the 8th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, Brixen, Italy, .
    • Knobloch, T., Langer, K.Antibody modified PLGA-nanoparticles: Introduction and quantification of amino groups.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Löw, K., Knobloch, T., Wagner, S., Wiehe, A., Langer, K., von Briesen, H.Cytotoxicity and intracellular accumulation of mTHPC and mTHPC-loaded PLGA-nanoparticles in colon carcinoma cells.Poster contributed to the 8th International Symposium on Photodynamic Therapy and Photodiagnosis in Clinical Practice, Brixen, Italy, .
    • Engel, A., Plöger, M., von Storp, B., Böker, A., Langer, K.Preparation of albumin nanoparticles by desolvation - Evaluation of process parameters I.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Plöger, M., von Storp, B., Böker, A., Engel, A., Langer, K.Preparation of albumin nanoparticles by desolvation - Evaluation of process parameters II.Poster contributed to the Internat. Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Valetta, Malta, .
    • Böker, A., Engel, A., Plöger, M., von Storp, B., Langer, K.Preparation of human serum albumin nanoparticles in the sub-100 nm size range.Poster contributed to the DPhG Annual Meeting, Jena, Germany, .
    • Vogel, V., Langer, K., Mäntele, W.Fluorescence spectroscopy, fluorescence imaging and analytical ultracentrifugation in controlled drug release and drug imaging.Poster contributed to the European Conference on the Spectroscopy of Biological Molecules, Palermo, Italy, .
    • Wagner, S., Anhorn, M.G., Kreuter, J., Langer, K., von Briesen, H.Specific targeting of cancer cells with doxorubicin-loaded nanoparticles.Poster contributed to the 36th Annual Meeting & Exposition of the Controlled Release Society, Copenhagen, Denmark, .
  • Dissertationen

    Anderski, JulianeNanopartikuläre Arzneiformen zur Photodynamischen Therapie.
    Mahlert, LauraZellbiologische Bewertung von Photosensibilisator-beladenen Nanopartikelformulierungen.
    Partikel, KatrinUntersuchungen zur Proteinadsorption an nanopartikulären Arzneistoffträgersystemen.
    Raudszus, BastianEntwicklung einer Nanoformulierung zur Überwindung der Blut-Hirn-Schranke.
    Mesken, JuliaNanopartikuläre Trägersysteme für DNA-Vektoren
    Pieper, SebastianHSA-basierte Nanopartikel als Trägersysteme zur Resistenzüberwindung von Tumorzellen
    Horster, LutzFeste orale Arzneiformen zur Applikation von schwer löslichen Arzneistoffen am Beispiel Photosensibilisatoren
    Thoma, FrederiqueEntwicklung einer nanopartikulären Formulierung zur Behandlung der Parkinsonschen Erkrankung
    Söbbing, JudithEntwicklung und Charakterisierung von Nanopartikeln für die photodynamische Tumortherapie
    Spek, SilviaEntwicklung und Charakterisierung nanopartikulärer Systeme zur Analyse von Partikel-Zell-Interaktionen
    Look, JenniferNeuartige Liganden-modifizierte Nanopartikel als Trägersysteme für Nukleinsäuren
    Fahrländer, Eva-MariaEntwicklung und Charakterisierung PEGylierter HSA-Nanopartikel
    Zlatev, IavorEntwicklung von Nanopartikeln als Träger für Alzheimer Therapeutika
    John, CorneliaAsymmetrische Fluss-Feldfluss-Fraktionierung zur Charakterisierung kolloidaler Systeme
    Hindel, StefanEntwicklung einer nanopartikulären Arzneimittelformulierung auf der Basis von PLGA zum aktiven Drug-Targeting von Doxorubicin an Tumorzellen mittels des monoklonalen Antikörpers DI17E6
    Häuser, ManuelEntwicklung pH-schaltbarer Nanopartikelsysteme zur intrazellulären Wirkstofffreisetzung
    von Storp, BernhardEntwicklung nanopartikulärer Arzneiformen für niedermolekulare Kinase-Inhibitoren zur Anwendung in der Tumortherapie
    Engel, AndreaNanopartikuläre Trägersysteme für Tetrapyrrole
    Plöger, MichaelEntwicklung nanopartikulärer Arzneiformen für biologisch aktive sekundäre Pflanzeninhaltsstoffe
    Böker, AnnePartikuläre Arzneiformen zur kontrollierten Proteinfreisetzung
    Dickschen, Kristin Josefine RuthÜberwindung der CYP2D6 vermittelten Tamoxifenresistenz bei postmenopausalen Brustkrebs: ein PBPK-Ansatz
    Klassert, DeniseAngiogenes Potential chemoresistenter und persistenter HCMV-infizierter Neuroblastomzellen
    Geiler, JaninaUntersuchungen der Immunreaktion in Influenza-A-infizierten Zellen und Analyse von potentiellen antiviralen Substanzen
    Holzer, MelisandeAntikörperbeladene PLGA-Nanopartikel als Trägersystem für eine verzögerte Wirkstofffreisetzung in der Tumortherapie
    Wacker, MatthiasEntwicklung zellspezifischer Arzneistoffträger zur Tumortherapie

Lehre